These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 27773526)
21. Structure and function of fibroblast growth factor. Gambarini AG; Miranda MT; Viviani W; Oyama Júnior S; Kiyota S; Toma IN Braz J Med Biol Res; 1996 Jul; 29(7):835-9. PubMed ID: 9070372 [TBL] [Abstract][Full Text] [Related]
22. Structural requirements of FGF-1 for receptor binding and translocation into cells. Zakrzewska M; Krowarsch D; Wiedlocha A; Olsnes S; Otlewski J Biochemistry; 2006 Dec; 45(51):15338-48. PubMed ID: 17176056 [TBL] [Abstract][Full Text] [Related]
23. Differential effect of cell-associated heparan sulfates on the binding of keratinocyte growth factor (KGF) and acidic fibroblast growth factor to the KGF receptor. Reich-Slotky R; Bonneh-Barkay D; Shaoul E; Bluma B; Svahn CM; Ron D J Biol Chem; 1994 Dec; 269(51):32279-85. PubMed ID: 7528211 [TBL] [Abstract][Full Text] [Related]
24. Molecular characteristics of fibroblast growth factor-fibroblast growth factor receptor-heparin-like glycosaminoglycan complex. Venkataraman G; Raman R; Sasisekharan V; Sasisekharan R Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3658-63. PubMed ID: 10097093 [TBL] [Abstract][Full Text] [Related]
25. Design of fully active FGF-1 variants with increased stability. Zakrzewska M; Krowarsch D; Wiedlocha A; Otlewski J Protein Eng Des Sel; 2004 Aug; 17(8):603-11. PubMed ID: 15469994 [TBL] [Abstract][Full Text] [Related]
26. Structural basis for interaction of FGF-1, FGF-2, and FGF-7 with different heparan sulfate motifs. Ye S; Luo Y; Lu W; Jones RB; Linhardt RJ; Capila I; Toida T; Kan M; Pelletier H; McKeehan WL Biochemistry; 2001 Dec; 40(48):14429-39. PubMed ID: 11724555 [TBL] [Abstract][Full Text] [Related]
27. Effects of mutations of a phosphorylation site in an exposed loop in acidic fibroblast growth factor. Klingenberg O; Wiedlocha A; Olsnes S J Biol Chem; 1999 Jun; 274(25):18081-6. PubMed ID: 10364261 [TBL] [Abstract][Full Text] [Related]
28. Symmetric primary and tertiary structure mutations within a symmetric superfold: a solution, not a constraint, to achieve a foldable polypeptide. Brych SR; Dubey VK; Bienkiewicz E; Lee J; Logan TM; Blaber M J Mol Biol; 2004 Nov; 344(3):769-80. PubMed ID: 15533444 [TBL] [Abstract][Full Text] [Related]
29. Modulation of fibroblast growth factor-2 receptor binding, dimerization, signaling, and angiogenic activity by a synthetic heparin-mimicking polyanionic compound. Miao HQ; Ornitz DM; Aingorn E; Ben-Sasson SA; Vlodavsky I J Clin Invest; 1997 Apr; 99(7):1565-75. PubMed ID: 9120000 [TBL] [Abstract][Full Text] [Related]
30. Redesigning symmetry-related "mini-core" regions of FGF-1 to increase primary structure symmetry: thermodynamic and functional consequences of structural symmetry. Dubey VK; Lee J; Blaber M Protein Sci; 2005 Sep; 14(9):2315-23. PubMed ID: 16081654 [TBL] [Abstract][Full Text] [Related]
31. Similarities and differences between the effects of heparin and glypican-1 on the bioactivity of acidic fibroblast growth factor and the keratinocyte growth factor. Berman B; Ostrovsky O; Shlissel M; Lang T; Regan D; Vlodavsky I; Ishai-Michaeli R; Ron D J Biol Chem; 1999 Dec; 274(51):36132-8. PubMed ID: 10593896 [TBL] [Abstract][Full Text] [Related]
32. Both autocrine and paracrine effects of transfected acidic fibroblast growth factor are involved in the estrogen-independent and antiestrogen-resistant growth of MCF-7 breast cancer cells. Zhang L; Kharbanda S; Hanfelt J; Kern FG Cancer Res; 1998 Jan; 58(2):352-61. PubMed ID: 9443417 [TBL] [Abstract][Full Text] [Related]
33. Engineering a Cysteine-Free Form of Human Fibroblast Growth Factor-1 for "Second Generation" Therapeutic Application. Xia X; Kumru OS; Blaber SI; Middaugh CR; Li L; Ornitz DM; Sutherland MA; Tenorio CA; Blaber M J Pharm Sci; 2016 Apr; 105(4):1444-53. PubMed ID: 27019961 [TBL] [Abstract][Full Text] [Related]
34. Analysis of putative heparin-binding domains of fibroblast growth factor-1. Using site-directed mutagenesis and peptide analogues. Wong P; Hampton B; Szylobryt E; Gallagher AM; Jaye M; Burgess WH J Biol Chem; 1995 Oct; 270(43):25805-11. PubMed ID: 7592764 [TBL] [Abstract][Full Text] [Related]
36. Heparan sulfate proteoglycans function as receptors for fibroblast growth factor-2 activation of extracellular signal-regulated kinases 1 and 2. Chua CC; Rahimi N; Forsten-Williams K; Nugent MA Circ Res; 2004 Feb; 94(3):316-23. PubMed ID: 14684627 [TBL] [Abstract][Full Text] [Related]
37. Engineering of an FGF-proteoglycan fusion protein with heparin-independent, mitogenic activity. Yoneda A; Asada M; Oda Y; Suzuki M; Imamura T Nat Biotechnol; 2000 Jun; 18(6):641-4. PubMed ID: 10835602 [TBL] [Abstract][Full Text] [Related]
38. Structure of a heparin-linked biologically active dimer of fibroblast growth factor. DiGabriele AD; Lax I; Chen DI; Svahn CM; Jaye M; Schlessinger J; Hendrickson WA Nature; 1998 Jun; 393(6687):812-7. PubMed ID: 9655399 [TBL] [Abstract][Full Text] [Related]
39. SHuffle™ T7 strain is capable of producing high amount of recombinant human fibroblast growth factor-1 (rhFGF-1) with proper physicochemical and biological properties. Nasiri M; Babaie J; Amiri S; Azimi E; Shamshiri S; Khalaj V; Golkar M; Fard-Esfahani P J Biotechnol; 2017 Oct; 259():30-38. PubMed ID: 28827102 [TBL] [Abstract][Full Text] [Related]
40. Characterization of the murine BEK fibroblast growth factor (FGF) receptor: activation by three members of the FGF family and requirement for heparin. Mansukhani A; Dell'Era P; Moscatelli D; Kornbluth S; Hanafusa H; Basilico C Proc Natl Acad Sci U S A; 1992 Apr; 89(8):3305-9. PubMed ID: 1373495 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]